Skip to main content
Clinical Trials/NCT07575724
NCT07575724Not yet recruitingPhase 2

Comparison of the Effects of Needle Biopsy Tract Resection and Non-resection on Recurrence Rate in Patients With Primary Extremity Sarcoma: Study Protocol of a Randomized, Non-inferior Clinical Trial

Second Affiliated Hospital, School of Medicine, Zhejiang University2 sites in 1 country3,300 target enrollmentStarted: December 1, 2026Last updated:
Interventions

Trial Snapshot

Phase
Phase 2
Status
Not yet recruiting
Sponsor
Enrollment
3,300
Locations
2

Study Overview

Brief Summary

This randomized, non-inferiority clinical trial aims to evaluate whether non-resection of needle biopsy tract is non-inferior to routine biopsy tract resection in terms of local recurrence in patients with primary extremity musculoskeletal sarcoma undergoing en-bloc surgical treatment.

Biopsy tract resection is traditionally recommended to reduce the risk of tumor seeding; however, its benefit in reducing recurrence has not been definitively demonstrated, particularly when core needle biopsy is widely used. Also, avoiding biopsy tract resection may preserve uninvolved tissue without compromising oncologic safety.

The primary objective of this study is to compare local recurrence rates between patients who undergo biopsy tract resection and those who do not. Secondary objectives include comparisons of surgical complications, functional outcomes, overall survival, and progression-free survival.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
5 Years to — (Child, Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Histologically confirmed diagnosis of primary bone or soft tissue sarcoma of the extremities (or highly suspected sarcoma);
  • Candidate for limb-sparing surgery and capable of en-bloc resection;
  • Age ≥ 5 years;
  • ECOG performance status 0-2;
  • Able to understand and sign informed consent.

Exclusion Criteria

  • Presence of distant metastasis (e.g., lung, bone, or other sites) or unresectable skip lesions;
  • Patients deemed, based on preoperative multidisciplinary team (MDT) evaluation, unlikely to achieve adequate surgical margins and therefore only eligible for debulking or palliative surgery;
  • Patients with inconclusive needle biopsy results requiring open biopsy for definitive diagnosis;
  • Patients requiring amputation;
  • Patients who have received prior treatment for the tumor at non-participating centers;
  • Patients with an expected survival of less than 2 years;
  • Patients in whom the biopsy tract completely lies within the planned tumor resection field;
  • Patients who refuse to provide written informed consent.

Arms & Interventions

tract resection group

Experimental

Intervention: biopsy tract resection (Procedure)

tract non-section group

Active Comparator

Intervention: biopsy tract non-resection (Procedure)

Investigators

Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials